c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
about
Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro--implication for drug developmentStructural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase.Targeting the hepatocyte growth factor-cMET axis in cancer therapyDiscovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy?c-Met as a Target for Personalized TherapyAbl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and MotilityRoles of c-Met and RON kinases in tumor progression and their potential as therapeutic targetsGastrointestinal hormones cause rapid c-Met receptor down-regulation by a novel mechanism involving clathrin-mediated endocytosis and a lysosome-dependent mechanismMelanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through METHepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition.Cooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy.Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agentsPHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cellsAcquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumoursSpecific and nontoxic silencing in mammalian cells with expressed long dsRNAs.Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion.Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review.Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cellsPeptides and peptide hormones for molecular imaging and disease diagnosisValproic acid, targets papillary thyroid cancer through inhibition of c-Met signalling pathwayCharacterization of a human cell line stably over-expressing the candidate oncogene, dual specificity phosphatase 12.MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas.Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myelomaFibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion.Pathway analysis of breast cancer genome-wide association study highlights three pathways and one canonical signaling cascade.(-)-Epigallocatechin-3-gallate inhibits Met signaling, proliferation, and invasiveness in human colon cancer cells.Detection of estrogen-independent growth-stimulating activity in breast cancer tissues: implication for tumor aggressivenessPreclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET.Development of c-MET pathway inhibitors.Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102Targeting MET Amplification as a New Oncogenic Driver.Ubiquitination-dependent regulation of signaling receptors in cancer.CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells.Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail.Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma.HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancerVasculature-specific MRI reveals differential anti-angiogenic effects of a biomimetic peptide in an orthotopic breast cancer model
P2860
Q21132280-F5D8E402-E2B8-4E09-93D4-E4BB9004F11BQ24307789-79AE5834-811D-4B59-93E0-CAF68D55E476Q24606259-5530C8F2-99BD-408E-8F93-887BDB7CBC60Q24608143-28FF865B-A103-4D1E-BE42-A498E65D7D21Q26739760-06ED53FD-CFA4-46A0-8B68-019AC563DE4BQ26775483-497660D2-57A4-41B1-848B-7E3F02DAD1BAQ27308835-205D8863-2494-4876-9A10-FFF25DA7FDEDQ28081193-439770ED-EF59-4998-8376-0FE37074E1F6Q28570307-7CF8258B-73FE-43CC-B92D-29140A938638Q29618139-C270E70A-DAD7-4749-995A-B9C923BB89A0Q30414265-75B82D64-FDE8-48E7-A5FF-D663CC8F55D6Q30422676-37A43FD3-CCAD-4119-96DB-66446440DF44Q30492361-4039934E-EF8E-4799-9815-148780E723E7Q30502341-DBCAE76A-AAEB-4F81-81AF-DA81AAD67696Q30917936-74C6CE7A-8D4C-4B0D-A686-B7C352FBE047Q31151258-AF63B5BE-4116-4E84-A1E9-2217ECFDED14Q33254360-29396A01-5CBB-403A-9DED-500D43C95114Q33529782-9A10636A-2718-4218-9031-71F6739347DFQ33649756-B946E0F6-3F63-4D8F-9259-C72A12305213Q33823715-A23E874B-08D6-45DC-AE98-B92438444F9CQ33846924-732795B2-11CB-469E-860A-D4DF063BA868Q33850376-BA215482-0702-44BC-9FC7-FBB64A222639Q33893715-7986DA8B-AA11-4351-B0C8-20E8625F4871Q33906031-91C9B2E8-1D55-45F4-A06E-8EF2E7AC2254Q33918113-8B978524-CD8A-4521-B3CE-ECD7E94447A1Q33934433-EF4D5C81-9B58-45C9-A9B4-65792EE65796Q34008159-5B5F9DB3-43D4-4A40-95E1-DC40ED1B73CDQ34044173-D4CD2F8E-6EFA-4610-94F8-11A7A61ABB3CQ34115972-86D6D927-F074-45B2-936F-E34F6FDDFFC2Q34164758-0E581A39-768D-43D1-8393-CAC34372DF1AQ34198905-16FAE0D9-8360-4663-8D2F-CC0A5C3EAD59Q34293078-11E5C692-F5C6-477A-A4D5-6698A7B0E745Q34309927-CFFD5434-5268-4236-8015-6D76213A1C43Q34365210-636EB892-69E2-42A8-A09E-28BE01AF7C36Q34440437-6A347E73-60D7-4A96-98FF-CBDF9DDACEFCQ34972866-0D3B7B87-A4AB-4C56-B5D6-F502F5DFE5A1Q35051790-A1492D2C-AC0E-44C5-BA1F-6A774AA11DDFQ35083852-5C30D8B7-755C-4012-BF91-8C996CF338EDQ35174872-48402ACC-DFEE-4D1A-80E3-C5E7F0744349Q35196265-2514D248-B67A-42DD-BC31-0F2166A5E0E8
P2860
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
c-Met as a target for human ca ...... for therapeutic intervention.
@ast
c-Met as a target for human ca ...... for therapeutic intervention.
@en
c-Met as a target for human ca ...... for therapeutic intervention.
@nl
type
label
c-Met as a target for human ca ...... for therapeutic intervention.
@ast
c-Met as a target for human ca ...... for therapeutic intervention.
@en
c-Met as a target for human ca ...... for therapeutic intervention.
@nl
prefLabel
c-Met as a target for human ca ...... for therapeutic intervention.
@ast
c-Met as a target for human ca ...... for therapeutic intervention.
@en
c-Met as a target for human ca ...... for therapeutic intervention.
@nl
P1433
P1476
c-Met as a target for human ca ...... for therapeutic intervention.
@en
P2093
James G Christensen
Jon Burrows
P356
10.1016/J.CANLET.2004.09.044
P407
P50
P577
2004-11-11T00:00:00Z